#Pharma #Healthcare #GLP1 #ObesityCare #Innovation #Teva #NovoNordisk To view or add a comment, sign in Lilly Eats Novos Lunch The $150 Billion Weight-Loss War Just Flipped For years, Novo Nordisk owned the GLP-1 revolution with Wegovy and Ozempic
L-Carnitine plays a vital role in reducing exercise-induced muscle damage, helping to speed up recovery and decrease post-workout soreness
Novo's newly acquired drug is a clear potential competitor to retatrutide because it similarly uses a three-pronged approach to promoting weight loss and regulating blood sugar
NAC, as a precursor for reduced GSH, demonstrates antioxidant, anti-inflammatory and immunomodulatory effects, which may prove beneficial in modulating any excess inflammatory activation during COVID-19 611,612
Obesity is now seen more like a chronic disease, which means it may need ongoing treatment and follow-up